Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) today announced that recent studies have shown that SPL7013, the active ingredient in its topical microbicide VivaGel(R), inhibits clinically-relevant strains of the human papillomavirus (HPV) in laboratory tests.
Australia's adult stem cell company, Mesoblast Limited (ASX: MSB; USOTC: MBLTY), today announced successful long-term results in its osteoarthritis preclinical trials. A single injection of its proprietary allogeneic, or "off-the-shelf", adult stem cells into arthritic knees provided sustained protection against cartilage destruction and degeneration for up to nine months.
Acrux (ASX: ACR)(PNK:ARUXF) today announced that Evamist(tm), the first product utilising its unique skin spray drug delivery technology, has been launched by US licensee KV Pharmaceutical Company (NYSE: KVa/KVb) into one of the largest therapeutic categories in women's healthcare.
Starpharma Holdings Ltd (ASX: SPL)(OTCQX: SPHRY) has filed a patent application for the use of SPL7013, the active ingredient in VivaGel(R), to inhibit hyaluronidase activity in the treatment or prevention of a number of diseases. The inhibitory activity was discovered during studies on the contraceptive activity of SPL7013, in which effects on hyaluronidase were examined due to the enzyme's involvement in the fertilization process.
Leading Australia-based medical diagnostics-devices company, Compumedics Limited (ASX: CMP), is pleased to announce that it is on track with its re-structure and growth trajectory. Shareholders, investors, and interested parties are invited to listen to highlights from the Boardroom Radio broadcast of the roadshow presentations that senior management recently delivered in Melbourne, then in Sydney on 19 March 2008. A clickable link is found at the end of this document for a snapshot of the Sydney presentation. The presentations focused on Compumedics' turnaround and recent results.
Australia's adult stem cell company, Mesoblast Limited (ASX: MSB)(USOTC: MBLTY), today announced that it will accelerate its clinical trial timetable towards commencement of a Phase 3 trial in spinal fusion by mid 2009 following encouraging preliminary safety data from its ongoing Phase 2 clinical trial.
Starpharma Holdings Ltd (ASX:SPL)(OTCQX: SPHRY) today announced the signing of an agreement with Unilever, to co-develop a research tool using Starpharma's Priostar(R) dendrimer technology. An undisclosed fee is payable to Starpharma's US subsidiary DNT Inc as part of the arrangement.
